Zhe Sha

Zhe Sha is a Principal Scientist at Kymera Therapeutics since August 2022, leading biology efforts in E3 Ubiquitin Ligase and Molecular Glue Discovery Projects, specializing in CRISPR KO and HIBIT KI cell line generation, and providing biology support for immunology and oncology programs while managing an associate scientist and CRO. Prior to this role, Zhe Sha served as a Principal Scientist at UCB from February 2019 to August 2022, overseeing the Autophagy TPD platform and developing cell-based assays for PROTAC and molecular glue screening, in addition to supporting immunology and bone disease projects. Zhe Sha previously held the position of Senior Scientist at UCB, contributing to neuronal disease TPD projects, developing CRISPR-based cell lines, and conducting in-cell Protein proximity and ubiquitination assays, while also collaborating across multiple sites and receiving a silver SPOT award.